Taylor & Francis Group
2 files

Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion

posted on 2022-01-11, 09:40 authored by Susanna B. Park, Stefano Tamburin, Angelo Schenone, Ian R. Kleckner, Roser Velasco, Paola Alberti, Grace Kanzawa-Lee, Maryam Lustberg, Susan G. Dorsey, Elisa Mantovani, Mehrnaz Hamedani, Andreas A. Argyriou, Guido Cavaletti, Ahmet Hoke

Chemotherapy-induced peripheral neurotoxicity (CIPN) remains a significant toxicity in cancer survivors without preventative strategies or rehabilitation. Exercise and physical activity-based interventions have demonstrated promise in reducing existing CIPN symptoms and potentially preventing toxicity, however there is a significant gap in evidence due to the lack of quality clinical trials and appropriate outcome measures.

We systematically reviewed outcome measures in CIPN exercise and physical rehabilitation studies with expert panel consensus via the Peripheral Nerve Society Toxic Neuropathy Consortium to provide recommendations for future trials. Across 26 studies, 75 outcome measures were identified and grouped into 16 domains within three core areas – measures of manifestations of CIPN (e.g. symptoms/signs), measures of the impact of CIPN and other outcome measures.

This article provides a conceptual framework for CIPN outcome measures and highlights the need for definition of a core outcome measures set. The authors provide recommendations for CIPN exercise and physical rehabilitation trial design and outcome measure selection. The development of a core outcome measure set will be critical in the search for neuroprotective and treatment approaches to support cancer survivors and to address the gap in the identification of effective rehabilitation and treatment options for CIPN.


This work was supported by the National Health and Medical Research Council of Australia under Grants (#1148595, #1080521 to SBP), Cancer Institute NSW under Grant (#14/TPG/1-05 to SB Park), National Cancer Institute under Grant (K07CA221931 to IR Kleckner), Instituto de Salud Carlos III under Grant (project PI20/00283 co‐funded by European Regional Development Fund. ERDF, a way to build Europe, to R Velasco), CERCA Programme /Generalitat de Catalunya for institutional support to R Velasco and University of Milano-Bicocca Under Grant (‘Bicocca Starting Grant’ to P Alberti). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.